Aim. To investigate the role of miR-26b and Mcl-1 in TRAIL-inducing cell death in hepatocellular carcinoma. Methods. The expression of miR-26b and Mcl-1 in HCC was detected by RT-qPCR and western blot. The regulation of Mcl-1 by miR-26b was determined by luciferase reporter assay. MTT and flow cytometry were employed to detect the cell viability and apoptosis. Results. miR-26b is commonly downregulated in HCC cell lines compared with the LO2 cell line. In contrast, the Mcl-1 expression is upregulated in HCC cell lines. Bioinformatic analysis identified a putative target site in the Mcl-1 mRNA for miR-26b and luciferase reporter assay showed that miR-26b directly targeted the 3 -UTR (3 -Untranslated Regions) of Mcl-1 mRNA. Transfection of miR-26b mimics suppressed Mcl-1 expression in HCC cells and sensitized the cancer cells to TRAIL (tumor necrosis factorrelated apoptosis-inducing ligand) cytotoxicity. In addition, transfection of HCC cells with Mcl-1 expression plasmid abolished the sensitization effect of miR-26b to TRAIL-inducing apoptosis. Conclusions. Our study showed that miR-26b was a negative regulator of Mcl-1 gene and sensitized TRAIL-inducing apoptosis in HCC cells, suggesting that the miR-26b-Mcl-1 pathway might be a novel target for the treatment of HCC.
Background
Hepatocellular carcinoma (HCC) is a worldwide problem hazard to human health, which has poor prognosis, short survival time, and is with the 3rd mortality rate within all cancers [1] . Researches in the past few decades revealed that a number of factors can increase the risk of developing HCC, such as hepatitis virus infection, metabolic diseases, and liver fibrosis [2, 3] . However, the pathogenesis of HCC is still not very clear, and high expression of some protective proteins in cells may be an important cause of HCC incidence [4] .
Mcl-1 is an antiapoptotic member in the Bcl-2 family proteins, which contains three BH (Bcl-2 homology) domains and plays antiapoptotic effects by binding to proapoptotic proteins Noxa, puma, bim, bid, and so forth [5] . Researches revealed that overexpression of Mcl-1 could be against the apoptotic stimulus such as TRAIL-(tumor necrosis factorrelated apoptosis-inducing ligand-) inducing cell death. In contrast, knockdown of Mcl-1 enhanced the TRAIL cytotoxicity [6] . Mcl-1 seems to be more widely distributed within the cell than other Bcl-2 proteins. Besides to mainly localize in the mitochondrial membrane, Mcl-1 has also been found in the nucleus and the cytoplasm [7] . Mcl-1 is highly expressed in a variety of human tumor tissues, such as breast cancer, colon cancer, lung cancer, ovarian cancer, prostate cancer, kidney cancer, and liver cancer [8, 9] . Although overexpression of Mcl-1 does not directly promote the proliferation of tumor cells, its ability to suppress apoptosis plays a key role for cancer cell to protect against the apoptosis-inducing effect caused by toxic factors. Protection from apoptosis via overexpression of Mcl-1 in tumor cells may represent a significant barrier to the effectiveness of chemotherapeutic agents [10, 11] .
MicroRNAs (miRNAs) are a class of small, endogenous, noncoding, single-stranded RNAs of 19-25 nucleotides cleaved from 70-100 nucleotide hairpin pre-miRNA precursors. miRNAs bind to the complementary sequences of the target mRNA 3 -UTR and then induce the mRNA degradation or translational repression, regulating the expression of the target genes [12, 13] . Currently, there are over 1,000 miRNAs that have been identified in human cells, regulating up to 60% of protein-coding genes in human genome [14] . miRNAs regulate a variety of physiological and pathological cellular processes, including cell growth, differentiation, proliferation, and apoptosis [15] . Recent studies have shown that about half of the human miRNAs are located in cancer-associated genomic regions and frequently dysregulated in cancer, suggesting that miRNAs play a key role in oncogenesis [16] . It is reported that the expression of miR-26b is dysregulated in many kinds of cancers, which is profoundly involved in oncogenesis, epithelialmesenchymal transition, and resistance to medical drugs [17, 18] . However, the function of miR-26b in HCC is still little known.
In the present study, bioinformatics analysis predicts that miR-26b potentially targets the Mcl-1 3 -UTR, which is confirmed by the luciferase assay. We demonstrated that miR26b could downregulate Mcl-1 expression in HCC cells by directly targeting the 3 -UTR of Mcl-1 mRNA. We also found that transfection of miR-26b mimics augments the TRAILinducing apoptosis and then we explored some underlying molecular mechanisms.
Materials and Methods

Reagents and Antibodies
. miR-26b mimics and negative control oligonucleotide (NC oligo) were purchased from RiboBio Company (China). The sequences of the above RNA oligos were as follows: miR-26b mimics: 5 -UUCAAGUAAUUCAGGAUAGGU-3 ; NC oligo: 5 -UGU-AAUAAUGGAACUCGGAUU-3 . 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), trypan blue, and Annexin V-FITC Apoptosis Detection Kit were obtained from Sigma-Aldrich (USA). Antibodies for rabbit antihuman Mcl-1 and rabbit anti-human -actin were purchased from Cell Signaling (USA). Human recombinant TRAIL was obtained from R&D Systems (USA).
Cell
Culture. Human HCC cell lines (HepG2, Hep3B, PLC, and Huh7) and the human embryo liver cell line (L02) were from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China), and cultured in DMEM basic medium (Gibco, USA) with 10% fetal bovine serum (FBS, Gibco, USA) at 37 ∘ C in a humidified 5% CO 2 incubator.
Mcl-1 mRNA Expression Assay by Quantitative PCR (qPCR).
Total RNA was extracted with TRIzol (Invitrogen, USA) and reverse-transcribed into cDNA with M-MLV Reverse Transcriptase (Invitrogen, USA) following the manufacturer's instructions. qPCR was performed using SYBR Green (TaKaRa, Japan) on the Applied Biosystems 7500 Real Time PCR System, taking GAPDH mRNA as internal control and the relative level of Mcl-1 expression was determined with the 2 −ΔΔCT method [19] . Quantitative PCR primer sequences are as follows. Mcl-1 forward: 5 -CGACGGCGTAACAAACT-3 , Mcl-1 reverse: 5 -GGAAGAACTCCACAAACCC-3 ; GAPDH forward: 5 -TGCCAAATATGATGACATCAAGAA-3, GAPDH reverse: 5 -GGAGTGGGTGTCGCTGTTG-3 .
miR-26b Expression Assay by Quantitative PCR (qPCR).
Total RNA was extracted with TRIzol. Since the miR-26b is only composed of 22 nucleotides, we used stem-loop RTqPCR (reverse transcription-qPCR) method [20] . Taking U6 small nuclear RNA (snRNA U6) as internal control, the relative level of miR-26b expression was determined with the 2 −ΔΔCT method. The primer sequences are as follows. miR26b RT primer: 5 -CTCAACTGGTGTCGTGGAGTCGG CAATTCAGTTGAGACCTATCC-3 ; U6 snRNA RT primer: 5 -AACGCTTCACGAATTTGCGT-3 . [21] . Results were represented as the ratio between the various treatments and the NC control.
Measurement of Cell Death and Apoptosis.
HepG2 cells were seeded into 6-well plates for 16 h and then transfected with the miR-26b or NC oligo (100 pmol/well) with/without plasmid (pEGFP-Mcl-1, pEGFP-N1, 4.0 g/well) for 24 h. TRAIL was then added (5 ng/mL final) in fresh media and the cells were treated for another 24 hours. Cell death was measured by trypan blue exclusion assay [22] ; the cell death rate was determined by calculating staining cells to total cells under optical microscope. Cell apoptosis was measured using Annexin V-FITC Apoptosis Detection Kit according to the manufacturer's instructions and analyzed using flow cytometry.
2.11. Statistical Analysis. SPSS 13.0 software was used for statistical analysis. Data were presented as the mean ± SD and derived from at least three independent experiments. Comparisons between two groups were made by Student'stest, and comparisons among three groups were made with ANOVA. values less than 0.05 were considered to be of statistical significance.
Results
HCC Cells Express High Level of Mcl-1 and Low Level of miR-26b.
To investigate the biological role of miR-26b in HCC cells, we first measured the levels of Mcl-1 and mature miR-26b in four HCC cell lines (HepG2, Hep3B, PLC, and Huh7) and LO2 cells which are derived from human embryo liver and described as the normal hepatocytes, although they are immortalized [23] . The results showed that the HCC cell lines expressed lower level of miR-26b (Figure 1(a) ) and higher Mcl-1 at both mRNA and protein levels (Figures 1(b 
miR-26b Sensitized TRAIL-Induced Viability Inhibition and Apoptosis in HepG2 Cells.
To study the role of miR26b in apoptosis regulation in HCC cells, we treated with TRAIL which is an apoptotic stimulus after transfection with miR-26b in HepG2 cells. As shown in Figures 3(a) and 3(b) , obvious cell viability inhibition and more cell death were observed in the combination group than in the control. However, in the groups treated with either miR-26b mimics or TRAIL alone, no significant cytotoxicity was observed. Then, the treated cells were collected and detected the apoptosis using Annexin V/PI staining on flow cytometry. As shown in Figure 3 (c), HepG2 cells were resistant to TRAILinduced apoptosis, as a low quantity of Annexin V positive cells was observed with flow cytometry. However, significant increase of apoptotic cells was observed in the sample treated with the combination of TRAIL and miR-26b mimics. These data suggest that overexpression of miR-26b would sensitize the cells to TRAIL cytotoxicity. 
Exogenous Mcl-1 Abolished the Sensitization of miR26b to TRAIL-Induced Cytotoxicity.
Mcl-1 is an antiapoptotic protein in the Bcl-2 family members, and downregulation of Mcl-1 induced cell growth inhibition in HCC cells [24] . Therefore, we speculated that the mechanism of miR-26b sensitized TRAIL-induced cytotoxicity was due to the downregulation of Mcl-1 caused by miR-26b. So we cotransfected with miR-26b and pEGFP-Mcl-1 before being treated with TRAIL in HepG2 cells. As shown in Figure 4 , transfection of pEGFP-Mcl-1 significantly inhibited the cytotoxicity of miR26b combining with TRAIL. Taken together, the data support a role for miR-26b-mediated Mcl-1 regulation that modulates cellular sensitivity to TRAIL.
Discussion
Previous researches have demonstrated that Mcl-1 is a key antiapoptotic protein in HCC cells. Sieghart et al. [9] showed that the tumor specimens overexpressed Mcl-1 in HCC patients; however, in paired samples of nontumor liver tissue adjacent to HCC, no positive staining was observed even if they were directly neighbouring tumor tissue, suggesting that the overexpression of Mcl-1 is tumor specific. Moreover, since liver tissue specific deletion of Mcl-1 does not induce apoptosis of normal hepatocytes, targeting Mcl-1 for HCC therapy might not harm healthy liver tissue [25, 26] .
Mcl-1 also plays an important role in other cancer cells. Thallinger et al. [27] reported that Mcl-1 antisense oligonucleotides treatment of SCID mice with melanoma subcutaneous tumors resulted in cancer sensitization to the chemotherapeutic drugs, accompanied by increased levels of apoptosis in tumor cells. Pancreatic adenocarcinoma is another cancer that overexpresses Mcl-1. Knockdown of Mcl-1 led to the cell death in a pancreatic cancer cell line, and loss of Mcl-1 sensitized the cancer cells to Gemcitabine [28] . These studies suggested that Mcl-1 may become a prospective target for cancer therapy.
MicroRNAs are endogenous and effective small molecules to influence multiple physiological processes via regulating relative gene expression. Recent studies show that the expression changes of miRNAs always lead to tumorigenesis [29] . Increasing evidence suggests that microRNAs play a role in carcinogenesis by altering transcription of oncogenes and tumor suppressor genes to promote the proliferation and metastasis as well as antiapoptosis for cancer cells [30] [31] [32] [33] . Therefore, subsets of miRNAs have been identified as potential diagnostic and prognostic markers in malignant tumours [34] . miR-26b has been reported to have extensive biological effects in cells [35] , and recent studies prove that miR-26b was always downregulated in multiple cancers. Li et al. [36] indicated that miR-26b plays a role as tumour suppressor gene in breast cancer by targeting the CDK8. Similarly, the miR-26b level was downregulated in HCC, which inhibits the epithelial-mesenchymal transition and cell proliferation [37] .
In this study, we demonstrate that miR-26b plays a role as a tumor suppressor in HCC cells. HCC cell lines expressed higher Mcl-1 and lower level of miR-26b compared with L02 cells, indicating that there was an inverse relationship between the expressions of Mcl-1 and miR-26b. Our data proved that miR-26b was a novel regulator of Mcl-1, through binding to 3 -UTR of Mcl-1 mRNA. Downregulation of Mcl-1 mediated by miR-26b significantly sensitized TRAILinduced viability inhibition and apoptosis in HepG2 cells and exogenous Mcl-1 abolished the sensitization of miR-26b to TRAIL-induced cytotoxicity.
Our study provides the first evidence that miR-26b was a novel regulator of Mcl-1, and Mcl-1 plays a key role in the sensitization effect of miR-26b on TRAIL-induced apoptosis in HCC in vitro. These results also suggested that miR26b/Mcl-1 pathway might act as a sensitizer for chemotherapy and may be a novel target for the treatment of HCC.
